Literature DB >> 35637395

Risk assessment of femoral pathological fracture in prostate cancer patients by computed tomography analysis.

Hajime Rikitake1, Keisuke Horiuchi2,3, Kosuke Miyai4, Michiro Susa1, Masahiro Inoue1, Eiko Taguchi1, Takahiro Ishizaka1, Kazuhiro Chiba1.   

Abstract

INTRODUCTION: Prostate cancer often forms osteoblastic lesions that appear as a high-dense shadow upon X-ray. Although the lesions may seem to increase bone strength, pathological fracture occurs in one in four patients with prostate cancer. The aim of this study is to elucidate the factors that may increase the risk of pathological fracture in patients with prostate cancer metastases in the proximal femur by analyzing computed tomography data.
MATERIALS AND METHODS: Computed tomography data of the femur of 62 prostate cancer patients were retrospectively analyzed. The patients were divided into three groups based on the presence or absence of femoral metastatic lesions and pathological fracture. Surgical specimens of the proximal femur collected from patients who had a pathological fracture were histologically analyzed.
RESULTS: Bone density in the marrow area was increased in all cases with metastases compared with those with no metastases. Contrarily, the cortical bone density at the medial trochanter region was significantly lower in patients who had pathological fractures in the proximal femur than those who did not. Accordingly, histological analysis of the surgical specimens revealed that the affected cortical bone was osteopenic without any apparent new bone formation.
CONCLUSION: These results indicate that prostate cancer is less effective in inducing bone formation in the cortex than in the marrow and that the decrease in the cortical bone density at the medial trochanter region leads to an increased risk of pathological fracture. Therefore, a previously undocumented risk factor for pathological fracture in prostate cancer patients is presented.
© 2022. The Japanese Society Bone and Mineral Research.

Entities:  

Keywords:  Computed tomography; Femoral neck; Osteoblastic skeletal metastases; Pathological fracture; Prostate cancer

Mesh:

Year:  2022        PMID: 35637395     DOI: 10.1007/s00774-022-01338-2

Source DB:  PubMed          Journal:  J Bone Miner Metab        ISSN: 0914-8779            Impact factor:   2.626


  22 in total

Review 1.  Clinical features of metastatic bone disease and risk of skeletal morbidity.

Authors:  Robert E Coleman
Journal:  Clin Cancer Res       Date:  2006-10-15       Impact factor: 12.531

2.  Healthcare utilization and costs associated with skeletal-related events in prostate cancer patients with bone metastases.

Authors:  M Hagiwara; T E Delea; M W Saville; K Chung
Journal:  Prostate Cancer Prostatic Dis       Date:  2012-11-13       Impact factor: 5.554

Review 3.  Osteoblasts in prostate cancer metastasis to bone.

Authors:  Christopher J Logothetis; Sue-Hwa Lin
Journal:  Nat Rev Cancer       Date:  2005-01       Impact factor: 60.716

Review 4.  Prevention of Prostate Cancer Morbidity and Mortality: Primary Prevention and Early Detection.

Authors:  Michael J Barry; Leigh H Simmons
Journal:  Med Clin North Am       Date:  2017-07       Impact factor: 5.456

5.  10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer.

Authors:  Freddie C Hamdy; Jenny L Donovan; J Athene Lane; Malcolm Mason; Chris Metcalfe; Peter Holding; Michael Davis; Tim J Peters; Emma L Turner; Richard M Martin; Jon Oxley; Mary Robinson; John Staffurth; Eleanor Walsh; Prasad Bollina; James Catto; Andrew Doble; Alan Doherty; David Gillatt; Roger Kockelbergh; Howard Kynaston; Alan Paul; Philip Powell; Stephen Prescott; Derek J Rosario; Edward Rowe; David E Neal
Journal:  N Engl J Med       Date:  2016-09-14       Impact factor: 91.245

Review 6.  Skeletal complications of malignancy.

Authors:  R E Coleman
Journal:  Cancer       Date:  1997-10-15       Impact factor: 6.860

7.  Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer.

Authors:  Fred Saad; Donald M Gleason; Robin Murray; Simon Tchekmedyian; Peter Venner; Louis Lacombe; Joseph L Chin; Jeferson J Vinholes; J Allen Goas; Ming Zheng
Journal:  J Natl Cancer Inst       Date:  2004-06-02       Impact factor: 13.506

8.  A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma.

Authors:  Fred Saad; Donald M Gleason; Robin Murray; Simon Tchekmedyian; Peter Venner; Louis Lacombe; Joseph L Chin; Jeferson J Vinholes; J Allen Goas; Bee Chen
Journal:  J Natl Cancer Inst       Date:  2002-10-02       Impact factor: 13.506

9.  Skeletal fractures negatively correlate with overall survival in men with prostate cancer.

Authors:  Michael G Oefelein; Vincent Ricchiuti; William Conrad; Martin I Resnick
Journal:  J Urol       Date:  2002-09       Impact factor: 7.450

Review 10.  The Diagnosis and Treatment of Prostate Cancer: A Review.

Authors:  Mark S Litwin; Hung-Jui Tan
Journal:  JAMA       Date:  2017-06-27       Impact factor: 56.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.